Overview

Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

HCC patients with tumors >5 cm in diameter, regardless of involvement in the intrahepatic and extrahepatic portal branches participated in the study. Patients were randomized allocated in liver transplantation (LT) only group and LT plus ADV-TK therapy group. All patients received orthotopic liver transplantation; in the LT plus ADV-TK group, ADV-TK therapy was delivered to patients twice.

Phase:

Phase 2

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborator:

Beijing YouAn Hospital

Treatments:

Ganciclovir
Ganciclovir triphosphate
Liver Extracts